Celltrion and Teva announce U.S. FDA acceptance of biologics license application for proposed biosimilar to rituxan® (rituximab)

7th July 2017 Uncategorised 0

Teva Pharmaceutical Industries

More: Celltrion and Teva announce U.S. FDA acceptance of biologics license application for proposed biosimilar to rituxan® (rituximab)
Source: MDlinx